Comments on “High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence”

Documenti analoghi

• High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence
  di: Kristen Andreatta, et al.
  Pubblicazione: (2024)
• Antibody‐dependent enhancement and neutralization against CVB4 investigated in vitro and in silico through an agent‐based model
  di: Corentin Morvan, et al.
  Pubblicazione: (2024)
• Macrophages can transmit coxsackievirus B4 to pancreatic cells and can impair these cells
  di: Inès Vergez, et al.
  Pubblicazione: (2024)
• Infection of RAW 264.7 Cells by Murine Leukemia Virus‐Derived Retroviral Pseudotype Expressing the Envelope Glycoprotein of EBOV Is Enhanced by Antibodies
  di: Chaldam Jespère Mbani, et al.
  Pubblicazione: (2025)
• People living with HIV co‐infected with the Kaposi Sarcoma‐associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma
  di: Dalila G. Suterio, et al.
  Pubblicazione: (2024)